A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

NCT02494258 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematologic Neoplasm
Neoplasms
Hematologic Malignancies

Interventions

DRUG: CC-486

Sponsor

Celgene